[{"Assets_0_Q2_USD":263863000.0,"CommonStockSharesOutstanding_0_Q2_shares":62607947.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-63799000.0,"NetIncomeLoss_1_Q2_USD":-39444000.0,"NetIncomeLoss_2_Q2_USD":-78402000.0,"StockholdersEquity_0_Q2_USD":131313000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1254000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":1419000.0,"Ticker":"DVAX","CIK":"1029142","name":"DYNAVAX TECHNOLOGIES CORP","OfficialName":"Dynavax Technologies Corporation Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1279198792.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180807"}]